CLINICAL SIGNIFICANCE OF NOVEL BIOMOLECULES SUCH AS GALECTIN-3, APOPTOSIS-INDUCING FACTOR, ENDOTHELIN, AND VEGF-A IN THE DIAGNOSIS OF CHRONIC HEART FAILURE

Authors:

Abstract:

The use of molecular biomarkers, alongside classical clinical and instrumental methods, is becoming increasingly relevant for the early diagnosis and prognosis of chronic heart failure. The study aimed to assess the diagnostic value of novel biomarkers (galectin-3, apoptosis-inducing factor, endothelin, and VEGF-A) by comparing their levels across various functional stages (I–II, III, IV) of chronic heart failure. The study involved 219 patients aged between 34 and 89 years who were diagnosed with CHF and examined and treated at the Clinical Medical Center between 2018 and 2024. The concentrations of the biomarkers galectin-3, AIF, endothelin, and VEGF-A in the blood serum were analyzed using the enzyme-linked immunosorbent assay (ELISA) method. More pronounced changes in the levels of the studied biomarkers were observed in patients with NYHA class IV chronic heart failure. In this group, compared to patients in NYHA class I, the concentration of AIF increased by 80 % (p<0.001), endothelin-1 by 51 % (p=0.037), and galectin-3 by 70 % (p<0.001), all of which were statistically significant. In contrast, the concentration of VEGF-A showed a tendency to decrease (p=0.251). Compared to NYHA class II, a statistically significant 2.4 fold decrease in VEGF-A concentration (p<0.001) was observed in the NYHA class IV. The analyses revealed that during chronic heart failure, the levels of galectin-3, AIF, endothelin-1, and VEGF-A change significantly depending on the functional stage of the disease, with a marked increase observed as the disease progresses.

Keywords:

chronic heart failure galectin-3 AIF endothelin-1 VEGF-A

References:

1. Voronkov LH, Berezin (Moderators) OYe, Zharinova VYu, Zhebel VM. Koval OA, Rudyka YuS, et al. Biolohichni markery ta yikh zastosuvannya pry sertseviy nedostatnosti. Ukrainian Journal of Cardiology, 2019; 26 (3): 11–22. http://nbuv.gov.ua/UJRN/Ukzh_2019_26_2_4 [in Ukrainian].
2. Miakinkova LO, Liulka YeM, Katerenchuk IP, Teslenko YV, Pysana BO. Rhythm control in patients with bradysystolic atrial fibrillation. World of medicine and biology, 2023; 85 (26): 157–161. doi: 10.26724/2079-8334-2023-3-85-157-161 [in Ukrainian].
3. Cheng Z, Cai K, Xu C, Zhan Q, Xu X. Xu D, et al. Prognostic Value of Serum Galectin‑3 in Chronic Heart Failure: A Meta‑Analysis. Frontiers in Cardiovascular Medicine. 2022; 9: 783707. doi: 10.3389/fcvm.2022.783707.
4. Dmour BA, Costache AD, Dmour A, Huzum B, Duca ȘT, Chetran A, et al. Could Endothelin-1 Be a Promising Neurohormonal Biomarker in Acute Heart Failure? Diagnostics. 2023; 13: 2277. https://doi.org/10.3390/ diagnostics 13132277.
5. Haryono A, Ramadhiani R, Ryanto GRT, Emoto N. Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going. Biology (Basel). 2022 May 16;11(5):759. doi: 10.3390/biology11050759.
6. Florek K, Mendyka D, Gomułka K. Vascular Endothelial Growth Factor (VEGF) and Its Role in the Cardiovascular System. Biomedicines. 2024; 12: 1055. https://doi.org/10.3390/biomedicines12051055.
7. Fonseka O, Gare SR, Chen X, Zhang J, Alatawi NH, Ross C, et al. Molecular Mechanisms Underlying Heart Failure and Their Therapeutic Potential. Cells, 2025; 14: 324. https://doi.org/10.3390/cells14050324.
8. Khan MS, Shahid I, Bennis A, Rakisheva A, Metra M, Butler J. Global epidemiology of heart failure. Nature reviews Cardiology. 2024; 21: 717-34. doi: 10.1038/s41569-024-01046-6.
9. Kobusiak-Prokopowicz M, Jołda-Mydłowska B, Grzebieniak T, Początek K, Mysiak A. Expression of Proinflammatory Factors, Proangiogenic Factors and Endostatin in Patients with Heart Failure and Different Grades of Collateral Circulation Development. Adv Clin Exp Med. 2015 Nov-Dec;24(6):987-94. doi: 10.17219/acem/33811.
10. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
11. Pannella M, Caliceti C, Fortini F, Aquila G, Vieceli Dalla Sega F, Pannuti A, et al. Serum From Advanced Heart Failure Patients Promotes Angiogenic Sprouting and Affects the Notch Pathway in Human Endothelial Cells. J Cell Physiol. 2016 Dec;231(12):2700-10. doi: 10.1002/jcp.25373.
12. Wu C, Lv Z, Li X, Zhou X, Mao W, Zhu M. Galectin-3 in Predicting Mortality of Heart Failure: A Systematic Review and Meta-Analysis. Heart Surg Forum. 2021 Mar 30;24(2):E327-E332. doi: 10.1532/hsf.3547.
13. Zaborska B, Sikora-Frąc M, Smarż K, Pilichowska-Paszkiet E, Budaj A, Sitkiewicz D, et al. The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand? Int. J. Mol. Sci. 2023; 24:13111. https://doi.org/10.3390/ijms 241713111.
14. Zhou Y, Zhu X, Cui H, Shi J, Yuan G, Shi S, et al. The Role of the VEGF Family in Coronary Heart Disease. Front Cardiovasc Med. 2021 Aug 24;8:738325. doi: 10.3389/fcvm.2021.738325.
15. Zong L, Liang Z. Apoptosis-inducing factor: a mitochondrial protein associated with metabolic diseases-a narrative review. Cardiovasc Diagn Ther. 2023 Jun 30;13(3):609-622. doi: 10.21037/cdt-23-123.

Publication:

«World of Medicine and Biology» Vol. 21 No. 93 (2025) , с. 13-17
УДК 616.12-008.46:616.153:577.1:615.07

DOI:

https://doi.org/10.26724/2079-8334-2025-3-93-13-17